Hyaluronate receptor (CD44) and integrin alpha4 (CD49d) are up-regulated on T cells during MS relapses.
A longitudinal study of peripheral blood T cell adhesion molecule expression was performed in 24 relapsing-remitting MS patients. There were 15 relapses in 11 patients during 15 months of observation. In comparison with remission, expression of hyaluronate receptor (CD44) was highly significant, and expression of integrin alpha4 (CD49d, VLA-4) significantly up-regulated during relapses. CD44 and CD49d are putative activity markers and CD44 a potential novel therapeutic target in MS.
Soilu-Hänninen
Merja
M
Department of Neurology, Kiinamyllynkatu 4-8, PL 52, FIN-20521, Turku, Finland. mersoi@utu.fi
Laaksonen
Mikko
M
Hänninen
Arno
A
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D015815:Cell Adhesion Molecules / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D039441:Integrin alpha4 / Q000378:metabolism*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D013601:T-Lymphocytes / Q000378:metabolism*; D015854:Up-Regulation
D000276:Adjuvants, Immunologic; D015815:Cell Adhesion Molecules; D018960:Hyaluronan Receptors; D039441:Integrin alpha4; D016899:Interferon-beta; D000068556:Interferon beta-1a